Special Issue "Role of Calcium Homeostasis in the Duchenne Muscular Dystrophy"
Deadline for manuscript submissions: closed (20 June 2023) | Viewed by 206
Duchenne muscular dystrophy (DMD), caused by mutations in the dystrophin gene, is an X-linked muscle degenerative disease present in 1.7–2.1 of every 10,000 male births. In DMD patients, dystrophin loss leads to the destabilization of the dystrophin glycoprotein complex and sarcolemma instability, resulting in functional deficits. The absence of functional dystrophin ultimately leads to the degeneration and death of skeletal and cardiac muscle, being replaced by fibrous tissue. Finally, patients progress to death because of respiratory or cardiac failure. Even with the numerous studies and clinical trials that have been performed, and the existence of several promising therapeutic strategies that are currently under development, there is presently no effective disease-modifying therapy, and many questions remain unanswered. As a major secondary event, an abnormal elevation of the intracellular calcium concentration (Ca2+)i in the dystrophin-deficient muscle contributes to disease progression in DMD, suggesting that targeting Ca2+-handling mechanisms could be a promising therapeutic strategy for DMD. Calcium homeostasis abnormalities are a common pathological feature demonstrated in animal models of this disease, as well as in dystrophic cells and DMD patients. It has been demonstrated that the sarcolemma, sarcoplasmic reticulum, and mitochondria may play a role in the abnormal and sustained elevation of (Ca2+)i levels. However, no treatment targeting calcium pathways has been successful, pointing out that the role of dystrophin is not fully understood and that the interplay between its function, calcium regulation, and muscle survival still requires in-depth basic research.
Dr. Stéphane Sebille
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Calcium homeostasis
- Duchenne muscular dystrophy
- Ion channels
- calcium signaling
- IPSC disease modeling
- endoplasmic reticulum